Skip to content
National Cancer Institute
U.S. National Institutes of Health
| www.cancer.gov
In English |
En español
Search
NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
Clinical Trials Search Results
Page Options
E-Mail This Search
Clinical Trial Questions?
Get Help:
1-800-4-CANCER
or
LiveHelp online chat
Quick Links
Help Using the NCI Clinical Trials Search Form
Educational Materials About Clinical Trials
About NCI's Cancer Clinical Trials Registry
Dictionary of Cancer Terms
NCI Drug Dictionary
View Content for:
Patients
Health Professionals
Display:
Title
Description with:
Locations
Eligibility
Full Trial Description
Custom
Results 1-7 of 7 for your search:
Drug:
plerixafor
Find trials that include:
Any drugs shown
Trial Status:
Closed
Hide Search Criteria
Show Search Criteria
Help with Results
Select All on Page
Sort by:
Phase of Trial
Title
Type of Trial
Status of Trial
Age Range
Sponsor of Trial
Protocol IDs
Show
10
25
50
100
200
Results per Page
1.
Mobilization of Stem Cells With AMD3100 in Non-Hodgkin's Lymphoma Patients
Phase:
Phase III
Type:
Treatment
Status:
Completed
Age:
18 to 78
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
AMD3100-3101
, NCT00103610
2.
Mobilization of Stem Cells With AMD3100 in Multiple Myeloma Patients
Phase:
Phase III
Type:
Treatment
Status:
Completed
Age:
18 to 78
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
AMD3100-3102
, NCT00103662
3.
Study Evaluating AMD3100 for Transplantation of Sibling Donor Stem Cells in Patients With Hematological Malignancies
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Closed
Age:
18 to 65
Sponsor:
Other
Protocol IDs:
03-0349
, NCT00241358
4.
AMD3100 Given to NHL and MM Patients to Increase the Number of PBSCs When Given a Mobilizing Regimen of G-CSF
Phase:
Phase II
Type:
Treatment
Status:
Completed
Age:
18 to 70
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
AMD3100-C201
, NCT00396266
5.
The Effect of Rituximab on Mobilization With AMD3100 Plus G-CSF in Patients With Relapsed or Refractory NHL or HD
Phase:
Phase II
Type:
Treatment
Status:
Closed
Age:
18 to 70
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
AMD31002113
, NCT00444912
6.
Evaluation of the Safety and Efficacy of the Addition of AMD3100 to a G-CSF Mobilization Regimen in Patients With Lymphoma (NHL and HD) and Multiple Myeloma (MM).
Phase:
Phase II
Type:
Supportive care
Status:
Closed
Age:
18 to 78
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
AMD3100-EU23
, EudraCT number: 2006-00424729, NCT00665314
7.
Safety Study of AMD3100 With G-CSF to Increase Peripheral Blood Stem Cells
Phase:
Phase I
Type:
Supportive care
Status:
Closed
Age:
18 to 70
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
H-18743
, NCT00291811
Select All on Page
Help with Results
NCI Home
|
Images Version
|
Contact Us
|
Policies
|
Accessibility
|
Viewing Files
|
FOIA
|
Site Help
|
Site Map
A Service of the National Cancer Institute